Chimeric ILT-Receptor (CIR™) Technology Effectively Targets HLA-G+ Hematologic & Solid Tumors for Fit-for- Purpose Activation of NK Cells
Time: 12:30 pm
day: Day 2 -Track A - AM
Details:
- Diving on how CIR™NK cells with fit-for-purpose activation can efficiently and persistently target cancer cells across multiple tumors
- Understanding in vivo performance and functional activity of CIR™NK cells in leukemia and solid tumors
